A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.

Related Keywords

California ,United States ,San Francisco ,Ireland ,Illinois ,Switzerland ,Americans ,Amgen Repatha ,Dave Ricks ,Kaiser Permanente ,Megan Craig ,Aaron Glick ,Bristol Myers Squibb Celgene ,David Balto ,Robin Feldman ,Lina Khan ,Cowen Co ,Zinc Health Services ,Henryj Kaiser Family Foundation ,Kaiser Family Foundation ,Kaiser Health News ,Emisar Pharma Services ,Department Of Justice ,Us District Court ,Federalist Society ,Eli Lilly Co ,Ascent Health Services ,Testimony In Congress ,Allergan ,University Of California College The Law ,Amgen ,Federal Trade Commission ,Horizon Therapeutics ,Chair Lina Khan ,California College ,Myers Squibb Celgene ,Zinc Health ,John Kness ,President Donald Trump ,Express Scripts ,Eli Lilly ,Drugs ,Dish ,Hearing ,Pharmacy ,Research ,Herapeutics ,Inc ,